Research ArticleOriginal Article

Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids

Lisi Zeng, Quanxing Liao, Haoran Zhao, Shengwei Jiang, Xianzi Yang, Hongsheng Tang, Qingjun He, Xiansheng Yang, Shuxian Fang, Jinfu He, Weiwen Cui, Laiqiang Huang, Shaohua Ma and Shuzhong Cui
Cancer Biology & Medicine August 2021, 18 (3) 750-762; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0566

References

  1. 1.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Franko J,
    3. Shi Q,
    4. Meyers JP,
    5. Maughan TS,
    6. Adams RA,
    7. Seymour MT, et al.
    Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016; 17: 1709–19.
    OpenUrlPubMed
  3. 3.↵
    2. Vassos N,
    3. Piso P.
    Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018; 19: 49.
    OpenUrl
  4. 4.↵
    2. Spratt JS,
    3. Adcock RA,
    4. Sherrill W,
    5. Travathen S.
    Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980; 40: 253–5.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Sugarbaker PH.
    Peritonectomy procedures. Ann Surg. 1995; 221: 29–42.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. van Driel WJ,
    3. Koole SN,
    4. Sikorska K,
    5. Schagen van Leeuwen JH,
    6. Schreuder HWR,
    7. Hermans RHM, et al.
    Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018; 378: 230–40.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Shuzhong C.
    Chinese expert consensus on the clinical application of hyperthermic intraperitoneal chemotherapy (2019 version). Natl Med J China. 2020; 100: 89–96. (in Chinese).
    OpenUrl
  8. 8.↵
    2. Koga Y,
    3. Ochiai A.
    Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors. Cells. 2019; 8: 418.
  9. 9.↵
    2. Jo Y,
    3. Choi N,
    4. Kim K,
    5. Koo HJ,
    6. Choi J,
    7. Kim HN.
    Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development. Theranostics. 2018; 8: 5259–75.
    OpenUrl
  10. 10.↵
    2. Liu HD,
    3. Xia BR,
    4. Jin MZ,
    5. Lou G.
    Organoid of ovarian cancer: genomic analysis and drug screening. Clin Transl Oncol. 2020; 22: 1240–51.
    OpenUrl
  11. 11.↵
    2. Vlachogiannis G,
    3. Hedayat S,
    4. Vatsiou A,
    5. Jamin Y,
    6. Fernandez-Mateos J,
    7. Khan K, et al.
    Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359: 920–6.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Kopper O,
    3. de Witte CJ,
    4. Lohmussaar K,
    5. Valle-Inclan JE,
    6. Hami N,
    7. Kester L, et al.
    An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019; 25: 838–49.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. He C,
    3. Ruan F,
    4. Jiang S,
    5. Zeng J,
    6. Yin H,
    7. Liu R, et al.
    Black phosphorus quantum dots cause nephrotoxicity in organoids, mice, and human cells. Small. 2020; 16: e2001371.
  14. 14.↵
    2. Zalcberg JR,
    3. Cunningham D,
    4. Van Cutsem E,
    5. Francois E,
    6. Schornagel J,
    7. Adenis A, et al.
    Zd1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex colorectal study group. J Clin Oncol. 1996; 14: 716–21.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Cunningham D,
    3. Zalcberg JR,
    4. Rath U,
    5. Olver I,
    6. Van Cutsem E,
    7. Svensson C, et al.
    ‘Tomudex’ (zd1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The ‘tomudex’ colorectal cancer study group. Eur J Cancer. 1995; 31A: 1945–54.
    OpenUrlCrossRef
  16. 16.↵
    2. Tsavaris N,
    3. Kosmas C,
    4. Vadiaka M,
    5. Koufos C.
    Raltitrexed (tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-fluorouracil/leucovorin chemotherapy. BMC cancer. 2002; 2: 2.
    OpenUrlPubMed
  17. 17.↵
    2. Wei N,
    3. Zhang B,
    4. Wang Y,
    5. He XH,
    6. Xu LC,
    7. Li GD, et al.
    Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. Clin Transl Oncol. 2019; 21: 443–50.
    OpenUrl
  18. 18.↵
    2. Fang X,
    3. Jiang Y,
    4. Feng L,
    5. Chen H,
    6. Zhen C,
    7. Ding M, et al.
    Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70. Cancer Cell Int. 2013; 13: 48.
    OpenUrl
  19. 19.↵
    2. Huang SH,
    3. Yang KJ,
    4. Wu JC,
    5. Chang KJ,
    6. Wang SM.
    Effects of hyperthermia on the cytoskeleton and focal adhesion proteins in a human thyroid carcinoma cell line. J Cell Biochem. 1999; 75: 327–37.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Eng OS,
    3. Turaga KK.
    Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. J Sur Oncol. 2019; 119: 613–5.
    OpenUrl
  21. 21.↵
    2. Wisselink DD,
    3. Braakhuis LLF,
    4. Gallo G,
    5. van Grevenstein WMU,
    6. van Dieren S,
    7. Kok NFM, et al.
    Systematic review of published literature on oxaliplatin and mitomycin c as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Crit Rev Oncol Hematol. 2019; 142: 119–29.
    OpenUrl
  22. 22.↵
    2. Aboulkheyr Es H,
    3. Montazeri L,
    4. Aref AR,
    5. Vosough M,
    6. Baharvand H.
    Personalized cancer medicine: an organoid approach. Trends Biotechnol. 2018; 36: 358–71.
    OpenUrl
  23. 23.
    2. Soragni A,
    3. Janzen DM,
    4. Johnson LM,
    5. Lindgren AG,
    6. Thai-Quynh Nguyen A,
    7. Tiourin E, et al.
    A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer cell. 2016; 29: 90–103.
    OpenUrlCrossRefPubMed
  24. 24.
    2. Crespo M,
    3. Vilar E,
    4. Tsai SY,
    5. Chang K,
    6. Amin S,
    7. Srinivasan T, et al.
    Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med. 2017; 23: 878–84.
    OpenUrlCrossRef
  25. 25.↵
    2. Hill SJ,
    3. Decker B,
    4. Roberts EA,
    5. Horowitz NS,
    6. Muto MG,
    7. Worley MJ, Jr.., et al.
    Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018; 8: 1404–21.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords